Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022 LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...

Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...

Unicycive Reports Key Findings from Independent Renal Dietitian Survey Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...

Unicycive Reports Key Findings from Market Research with Nephrologists Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...

OPEN MINDS Community Members, PsychU.org & PKDnetwork.org, Partner To Provide A Webinar Addressing Major Depressive Disorder In Chronic Kidney Disease Gettysburg, Pa, Dec. 03, 2019 (GLOBE NEWSWIRE) -- PsychU.org and PKDnetwork.org have joined forces to provide a cutting edge webinar that will address the mental health challenges of Major...